Interleukin-21: basic biology and implications for cancer and autoimmunity

Interleukin-21 (IL-21), a potent immunomodulatory four-alpha-helical-bundle type I cytokine, is produced by NKT and CD4(+) T cells and has pleiotropic effects on both innate and adaptive immune responses. These actions include positive effects such as enhanced proliferation of lymphoid cells, increa...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annual review of immunology 2008-01, Vol.26 (1), p.57-79
Hauptverfasser: Spolski, Rosanne, Leonard, Warren J
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 79
container_issue 1
container_start_page 57
container_title Annual review of immunology
container_volume 26
creator Spolski, Rosanne
Leonard, Warren J
description Interleukin-21 (IL-21), a potent immunomodulatory four-alpha-helical-bundle type I cytokine, is produced by NKT and CD4(+) T cells and has pleiotropic effects on both innate and adaptive immune responses. These actions include positive effects such as enhanced proliferation of lymphoid cells, increased cytotoxicity of CD8(+) T cells and natural killer (NK) cells, and differentiation of B cells into plasma cells. Conversely, IL-21 also has direct inhibitory effects on the antigen-presenting function of dendritic cells and can be proapoptotic for B cells and NK cells. IL-21 is also produced by Th17 cells and is a critical regulator of Th17 development. The regulatory activity of IL-21 is modulated by the differentiation state of its target cells as well as by other cytokines or costimulatory molecules. IL-21 has potent antitumor activity but is also associated with the development of autoimmune disease. IL-21 transcription is dependent on a calcium signal and NFAT sites, and IL-21 requires Stat3 for its signaling. The key to harnessing the power of IL-21 will depend on better understanding its range of biological actions, its mechanism of action, and the molecular basis of regulation of expression of IL-21 and its receptor.
doi_str_mv 10.1146/annurev.immunol.26.021607.090316
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70445267</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20658760</sourcerecordid><originalsourceid>FETCH-LOGICAL-a550t-f24b835f89f9921cfd43b0644e18ed3d6499a72412cc6b5cb9018041ece4381c3</originalsourceid><addsrcrecordid>eNqFkMtKxDAUQIMozvj4BelK3LTevBtXivhEcKPrkKapRNtkTFph_l6dKbh0dRf3cO7lIHSGocKYiXMTwpTcV-WHYQqxr4iogGABsgIFFIsdtMSc8ZISWe-iJUhKSuA1WaCDnN8BQFEq99ECS8Upx7BEjw9hdKl304cPJcEXRWOyt0XjYx_f1oUJbeGHVe-tGX0MuehiKqwJ1qXNzkxj3Dzjx_UR2utMn93xPA_R6-3Ny_V9-fR893B99VQazmEsO8KamvKuVp1SBNuuZbQBwZjDtWtpK5hSRhKGibWi4bZRgGtg2FnHaI0tPUSnW-8qxc_J5VEPPlvX9ya4OGUtgTFOhPwXJCB4LQX8gJdb0KaYc3KdXiU_mLTWGPRveD2H13N4TYTehtfb8D-Kk_nW1Ayu_RPMpek3mRKEjw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20658760</pqid></control><display><type>article</type><title>Interleukin-21: basic biology and implications for cancer and autoimmunity</title><source>Annual Reviews Complete A-Z List</source><source>MEDLINE</source><creator>Spolski, Rosanne ; Leonard, Warren J</creator><creatorcontrib>Spolski, Rosanne ; Leonard, Warren J</creatorcontrib><description>Interleukin-21 (IL-21), a potent immunomodulatory four-alpha-helical-bundle type I cytokine, is produced by NKT and CD4(+) T cells and has pleiotropic effects on both innate and adaptive immune responses. These actions include positive effects such as enhanced proliferation of lymphoid cells, increased cytotoxicity of CD8(+) T cells and natural killer (NK) cells, and differentiation of B cells into plasma cells. Conversely, IL-21 also has direct inhibitory effects on the antigen-presenting function of dendritic cells and can be proapoptotic for B cells and NK cells. IL-21 is also produced by Th17 cells and is a critical regulator of Th17 development. The regulatory activity of IL-21 is modulated by the differentiation state of its target cells as well as by other cytokines or costimulatory molecules. IL-21 has potent antitumor activity but is also associated with the development of autoimmune disease. IL-21 transcription is dependent on a calcium signal and NFAT sites, and IL-21 requires Stat3 for its signaling. The key to harnessing the power of IL-21 will depend on better understanding its range of biological actions, its mechanism of action, and the molecular basis of regulation of expression of IL-21 and its receptor.</description><identifier>ISSN: 0732-0582</identifier><identifier>EISSN: 1545-3278</identifier><identifier>DOI: 10.1146/annurev.immunol.26.021607.090316</identifier><identifier>PMID: 17953510</identifier><language>eng</language><publisher>United States</publisher><subject>Animals ; Autoimmune Diseases - drug therapy ; Autoimmune Diseases - immunology ; Autoimmune Diseases - metabolism ; Autoimmunity - physiology ; Dendritic Cells - physiology ; Humans ; Interleukins - antagonists &amp; inhibitors ; Interleukins - physiology ; Interleukins - therapeutic use ; Lymphocytes - physiology ; Neoplasms - drug therapy ; Neoplasms - immunology</subject><ispartof>Annual review of immunology, 2008-01, Vol.26 (1), p.57-79</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a550t-f24b835f89f9921cfd43b0644e18ed3d6499a72412cc6b5cb9018041ece4381c3</citedby><cites>FETCH-LOGICAL-a550t-f24b835f89f9921cfd43b0644e18ed3d6499a72412cc6b5cb9018041ece4381c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,4168,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17953510$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Spolski, Rosanne</creatorcontrib><creatorcontrib>Leonard, Warren J</creatorcontrib><title>Interleukin-21: basic biology and implications for cancer and autoimmunity</title><title>Annual review of immunology</title><addtitle>Annu Rev Immunol</addtitle><description>Interleukin-21 (IL-21), a potent immunomodulatory four-alpha-helical-bundle type I cytokine, is produced by NKT and CD4(+) T cells and has pleiotropic effects on both innate and adaptive immune responses. These actions include positive effects such as enhanced proliferation of lymphoid cells, increased cytotoxicity of CD8(+) T cells and natural killer (NK) cells, and differentiation of B cells into plasma cells. Conversely, IL-21 also has direct inhibitory effects on the antigen-presenting function of dendritic cells and can be proapoptotic for B cells and NK cells. IL-21 is also produced by Th17 cells and is a critical regulator of Th17 development. The regulatory activity of IL-21 is modulated by the differentiation state of its target cells as well as by other cytokines or costimulatory molecules. IL-21 has potent antitumor activity but is also associated with the development of autoimmune disease. IL-21 transcription is dependent on a calcium signal and NFAT sites, and IL-21 requires Stat3 for its signaling. The key to harnessing the power of IL-21 will depend on better understanding its range of biological actions, its mechanism of action, and the molecular basis of regulation of expression of IL-21 and its receptor.</description><subject>Animals</subject><subject>Autoimmune Diseases - drug therapy</subject><subject>Autoimmune Diseases - immunology</subject><subject>Autoimmune Diseases - metabolism</subject><subject>Autoimmunity - physiology</subject><subject>Dendritic Cells - physiology</subject><subject>Humans</subject><subject>Interleukins - antagonists &amp; inhibitors</subject><subject>Interleukins - physiology</subject><subject>Interleukins - therapeutic use</subject><subject>Lymphocytes - physiology</subject><subject>Neoplasms - drug therapy</subject><subject>Neoplasms - immunology</subject><issn>0732-0582</issn><issn>1545-3278</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkMtKxDAUQIMozvj4BelK3LTevBtXivhEcKPrkKapRNtkTFph_l6dKbh0dRf3cO7lIHSGocKYiXMTwpTcV-WHYQqxr4iogGABsgIFFIsdtMSc8ZISWe-iJUhKSuA1WaCDnN8BQFEq99ECS8Upx7BEjw9hdKl304cPJcEXRWOyt0XjYx_f1oUJbeGHVe-tGX0MuehiKqwJ1qXNzkxj3Dzjx_UR2utMn93xPA_R6-3Ny_V9-fR893B99VQazmEsO8KamvKuVp1SBNuuZbQBwZjDtWtpK5hSRhKGibWi4bZRgGtg2FnHaI0tPUSnW-8qxc_J5VEPPlvX9ya4OGUtgTFOhPwXJCB4LQX8gJdb0KaYc3KdXiU_mLTWGPRveD2H13N4TYTehtfb8D-Kk_nW1Ayu_RPMpek3mRKEjw</recordid><startdate>20080101</startdate><enddate>20080101</enddate><creator>Spolski, Rosanne</creator><creator>Leonard, Warren J</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>20080101</creationdate><title>Interleukin-21: basic biology and implications for cancer and autoimmunity</title><author>Spolski, Rosanne ; Leonard, Warren J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a550t-f24b835f89f9921cfd43b0644e18ed3d6499a72412cc6b5cb9018041ece4381c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Animals</topic><topic>Autoimmune Diseases - drug therapy</topic><topic>Autoimmune Diseases - immunology</topic><topic>Autoimmune Diseases - metabolism</topic><topic>Autoimmunity - physiology</topic><topic>Dendritic Cells - physiology</topic><topic>Humans</topic><topic>Interleukins - antagonists &amp; inhibitors</topic><topic>Interleukins - physiology</topic><topic>Interleukins - therapeutic use</topic><topic>Lymphocytes - physiology</topic><topic>Neoplasms - drug therapy</topic><topic>Neoplasms - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Spolski, Rosanne</creatorcontrib><creatorcontrib>Leonard, Warren J</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Annual review of immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Spolski, Rosanne</au><au>Leonard, Warren J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Interleukin-21: basic biology and implications for cancer and autoimmunity</atitle><jtitle>Annual review of immunology</jtitle><addtitle>Annu Rev Immunol</addtitle><date>2008-01-01</date><risdate>2008</risdate><volume>26</volume><issue>1</issue><spage>57</spage><epage>79</epage><pages>57-79</pages><issn>0732-0582</issn><eissn>1545-3278</eissn><abstract>Interleukin-21 (IL-21), a potent immunomodulatory four-alpha-helical-bundle type I cytokine, is produced by NKT and CD4(+) T cells and has pleiotropic effects on both innate and adaptive immune responses. These actions include positive effects such as enhanced proliferation of lymphoid cells, increased cytotoxicity of CD8(+) T cells and natural killer (NK) cells, and differentiation of B cells into plasma cells. Conversely, IL-21 also has direct inhibitory effects on the antigen-presenting function of dendritic cells and can be proapoptotic for B cells and NK cells. IL-21 is also produced by Th17 cells and is a critical regulator of Th17 development. The regulatory activity of IL-21 is modulated by the differentiation state of its target cells as well as by other cytokines or costimulatory molecules. IL-21 has potent antitumor activity but is also associated with the development of autoimmune disease. IL-21 transcription is dependent on a calcium signal and NFAT sites, and IL-21 requires Stat3 for its signaling. The key to harnessing the power of IL-21 will depend on better understanding its range of biological actions, its mechanism of action, and the molecular basis of regulation of expression of IL-21 and its receptor.</abstract><cop>United States</cop><pmid>17953510</pmid><doi>10.1146/annurev.immunol.26.021607.090316</doi><tpages>23</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0732-0582
ispartof Annual review of immunology, 2008-01, Vol.26 (1), p.57-79
issn 0732-0582
1545-3278
language eng
recordid cdi_proquest_miscellaneous_70445267
source Annual Reviews Complete A-Z List; MEDLINE
subjects Animals
Autoimmune Diseases - drug therapy
Autoimmune Diseases - immunology
Autoimmune Diseases - metabolism
Autoimmunity - physiology
Dendritic Cells - physiology
Humans
Interleukins - antagonists & inhibitors
Interleukins - physiology
Interleukins - therapeutic use
Lymphocytes - physiology
Neoplasms - drug therapy
Neoplasms - immunology
title Interleukin-21: basic biology and implications for cancer and autoimmunity
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T08%3A44%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Interleukin-21:%20basic%20biology%20and%20implications%20for%20cancer%20and%20autoimmunity&rft.jtitle=Annual%20review%20of%20immunology&rft.au=Spolski,%20Rosanne&rft.date=2008-01-01&rft.volume=26&rft.issue=1&rft.spage=57&rft.epage=79&rft.pages=57-79&rft.issn=0732-0582&rft.eissn=1545-3278&rft_id=info:doi/10.1146/annurev.immunol.26.021607.090316&rft_dat=%3Cproquest_cross%3E20658760%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20658760&rft_id=info:pmid/17953510&rfr_iscdi=true